Red Glead Discovery
Red Glead Discovery, a prominent name in the pharmaceutical and biotechnology sectors, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2010, the company has established itself as a leader in drug discovery and development, focusing on innovative solutions that streamline the research process. Specialising in preclinical services, Red Glead Discovery offers a unique blend of expertise in pharmacology, toxicology, and bioanalysis. Their commitment to quality and efficiency has garnered recognition within the industry, positioning them as a trusted partner for clients seeking to advance their drug development pipelines. With a strong emphasis on collaboration and scientific excellence, Red Glead Discovery continues to achieve significant milestones, contributing to the success of numerous projects in the life sciences arena.
DitchCarbon Score
How does Red Glead Discovery's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Red Glead Discovery's score of 25 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Red Glead Discovery's reported carbon emissions
Red Glead Discovery AB, headquartered in Sweden, has set ambitious climate commitments despite not having specific carbon emissions data available. The company has committed to reducing its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 38% by 2030, using 2021 as the base year. Additionally, Red Glead Discovery aims to achieve a significant reduction of 90% in total GHG emissions across all scopes (Scope 1, 2, and 3) by 2045, also from a 2021 baseline. These targets have been validated through the Science Based Targets initiative (SBTi), aligning with the global goal to limit warming to 1.5°C. The company is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. Red Glead Discovery's commitment to these targets reflects its dedication to sustainability and responsible environmental stewardship within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Red Glead Discovery is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
